爱美客大幅拉升，股价突破200元，拟收购韩国医美公司

Core Viewpoint - The company, Aimeike, is making a significant move towards international expansion by acquiring 85% of REGEN Biotech, a leading South Korean medical aesthetics company, for $190 million, which is expected to enhance its market position and drive future growth [1][2][3]. Group 1 - Aimeike's stock surged approximately 15%, surpassing 200 yuan, with a trading volume of nearly 3.1 billion yuan following the announcement of the acquisition [1]. - The acquisition involves Aimeike's wholly-owned subsidiary, Imeik (HK) Limited, and Aisheng Shourui (HK) Limited, establishing Imeik International Limited to facilitate the purchase [1][2]. - REGEN Biotech specializes in the research, production, and sales of medical materials, medical devices, and pharmaceuticals, with notable products including AestheFill and PowerFill [2]. Group 2 - The transaction is a key step in Aimeike's international strategy, aimed at solidifying its leading position in the medical aesthetics injection filler market and driving sustainable growth [2][3]. - Post-acquisition, the integration of resources between Aimeike and REGEN Biotech is expected to create synergies, enhancing product access to international markets and increasing revenue from these markets [3]. - The acquisition will allow Aimeike to consolidate REGEN Biotech into its financial statements, expanding its asset base and improving future profitability and core competitiveness [3].